REVERS: Study using postbiotics in AMD patients 18/11/2020
A study to assess the efficacy and safety of postbiotic supplementation in
1) Preventing AMD progression, its impact on the worsening of functional and anatomical assessment criteria in intermediate age-related macular degeneration (iAMD)
2) Slowing the progression rate of geographic atrophy (GA) in patients with late non-exudative AMD or macular dystrophies.
3) Improving the efficacy of antiangiogenic therapy in patients with choroidal neovascularisation and insufficient response to treatment.
Depending on the treatment group, subjects will be randomly assigned an approved nutritional supplement for the prevention of the progression of intermediate AMD (AREDS) or the same supplement enriched with postbiotics.
Patients older than 50 with intermediate AMD, geographic atrophy and choroidal neovascularisation in antiangiogenic treatment and with weak treatment response.
ABOUT THE SUPPLEMENT
Postbiotics are compounds that are usually secreted by bacteria that live in our intestine. They may have direct and clinically relevant immunomodulatory effects. Studies may be found on the use of postbiotics in healthy individuals to improve overall health or to relieve symptoms in various diseases.
The duration of the study will be one year, with a possible two-year extension.
Dry or atrophic AMDExudative or wet AMD